EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Downregulated ALDH2 Contributes to Tumor Progression and Targeted Therapy Resistance in Human Metastatic Melanoma Cells

Zili Zhai iD, Takeshi Yamauchi iD, Karenna Sandoval iD, Kira Villarreal, Man Wai Charlotte Kwong, Emily J Swanson, Aik Choon Tan iD, Mayumi Fujita iD

Cells · 17.06.2025 · 14 (12) · 913

DOI: 10.3390/cells14120913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 17.06.2025. Verfasst von Zili Zhai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Melanoma, Aldehyde Dehydrogenase, Mitochondrial, Down-Regulation, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAID NIH HHS, NIH/NI- 480 AAA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldehyde dehydrogenase 2 (ALDH2) is a crucial detoxifying enzyme that eliminates toxic aldehydes. ALDH2 deficiency has been linked to various human diseases, including certain cancers. We have previously reported ALDH2 downregulation in human melanoma tissues. Here, we further investigated the biological significance of ALDH2 downregulation in this malignancy. Analysis of TCGA dataset revealed that low ALDH2 expression correlates with poorer survival in metastatic melanoma. Examination of human metastatic melanoma cell lines confirmed that most had ALDH2 downregulation (ALDH2-low) compared to primary melanocytes. In contrast, a small subset of metastatic melanoma cell lines exhibited normal ALDH2 levels (ALDH2-normal). CRISPR/Cas9-mediated ALDH2 knockout in ALDH2-normal A375 cells promoted tumor growth and MAPK/ERK activation. Given the pivotal role of MAPK/ERK signaling in melanoma and cellular response to acetaldehyde, we compared A375 with ALDH2-low SK-MEL-28 and 1205Lu cells. ALDH2-low cells were intrinsically resistant to BRAF and MEK inhibitors, whereas A375 cells were not. However, A375 cells acquired resistance upon ALDH2 knockout. Furthermore, melanoma cells with acquired resistance to these inhibitors displayed further ALDH2 downregulation. Our findings indicate that ALDH2 downregulation contributes to melanoma progression and therapy resistance in BRAF-mutated human metastatic melanoma cells, highlighting ALDH2 as a potential prognostic marker and therapeutic target in metastatic melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAldehyde Dehydrogenase, MitochondrialDown-RegulationDrug Resistance, NeoplasmDisease ProgressionMolecular Targeted TherapyHumansCell Line, TumorAnimalsNeoplasm MetastasisGene Expression Regulation, NeoplasticMiceMAP Kinase Signaling SystemCell Proliferation

Stichwörter der Autor:innen

MAPK/ERKacetaldehydealdehyde dehydrogenase 2drug resistancemelanomatargeted therapy

Substanzen

Aldehyde Dehydrogenase, MitochondrialALDH2 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
  • Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
  • Department of Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, Aurora, CO 80045, USA.
  • Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

ORCID-Profile: Zili Zhai, Takeshi Yamauchi, Karenna Sandoval, Aik Choon Tan, Mayumi Fujita

Förderung

  • BLRD VA
  • NIAID NIH HHS
  • NIH/NI- 480 AAA
  • NIH/NIAID
  • NCI NIH HHS
  • NIAAA NIH HHS
  • NIAMS NIH HHS
  • Veterans Affairs Merit Review Award

Zitieren

APA

Zhai, Z., Yamauchi, T., Sandoval, K., Villarreal, K., Kwong, M. W. C., Swanson, E. J., Tan, A. C., & Fujita, M. (2025). Downregulated ALDH2 Contributes to Tumor Progression and Targeted Therapy Resistance in Human Metastatic Melanoma Cells. Cells, 14(12), 913. https://doi.org/10.3390/cells14120913

Vancouver

Zhai Z, Yamauchi T, Sandoval K, Villarreal K, Kwong MWC, Swanson EJ, et al. Downregulated ALDH2 Contributes to Tumor Progression and Targeted Therapy Resistance in Human Metastatic Melanoma Cells. Cells. 2025;14(12):913. doi:10.3390/cells14120913

BibTeX
@article{Zhai2025,
  author = {Zhai, Zili and Yamauchi, Takeshi and Sandoval, Karenna and Villarreal, Kira and Kwong, Man Wai Charlotte and Swanson, Emily J and Tan, Aik Choon and Fujita, Mayumi},
  title = {Downregulated ALDH2 Contributes to Tumor Progression and Targeted Therapy Resistance in Human Metastatic Melanoma Cells},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {12},
  pages = {913},
  doi = {10.3390/cells14120913}
}
Kostenlos starten →